Related Experiment Video
Updated: May 11, 2026
08:23
Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
Published on: November 29, 2019
Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in
Charlotte Teunissen1, Til Menge, Ayse Altintas
1Neurological Laboratory, Innogentecis and Roche, VU University Medical Center, Netherlands.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|May 23, 2013
Summary
Standardizing control groups in cerebrospinal fluid (CSF) biomarker research for multiple sclerosis (MS) is crucial. This study proposes consensus definitions and nomenclature for various control groups to enhance research quality and comparability.
Area of Science:
- Neurology
- Biomarker Research
- Clinical Trials
Background:
- Cerebrospinal fluid (CSF) biomarker research in multiple sclerosis (MS) requires well-defined control groups for accurate interpretation.
- Current research often lacks standardized definitions and nomenclature for control groups, hindering comparability and reproducibility.
- The selection and application of control groups in MS biomarker studies need rationalization.
Purpose of the Study:
- To propose consensus definitions and nomenclature for various control groups used in CSF biomarker research.
- To provide guidance on the rationalized application of these control groups in different study designs.
- To improve the quality and comparability of biomarker studies in MS and related neurological disorders.
Main Methods:
- Literature review and expert consensus to establish definitions for control groups.
- Development of a standardized nomenclature for control groups.
- Discussion of the application of proposed control groups in diagnostic, prognostic, and therapeutic response studies.
Main Results:
- Proposed definitions and nomenclature for: healthy controls (HCs), spinal anesthesia subjects (SASs), inflammatory neurological disease controls (INDCs), peripheral inflammatory neurological disease controls (PINDCs), non-inflammatory neurological controls (NINDCs), and symptomatic controls (SCs).
- Guidelines for applying these control groups in specific MS biomarker study designs.
- Emphasis on the benefits of uniform definitions for comparability and resource optimization.
Conclusions:
- Adoption of uniform definitions and nomenclature for control groups will significantly enhance the quality of CSF biomarker research in MS.
- Standardization will improve the comparability of findings across studies and optimize the use of research resources.
- This initiative aims to advance the field of MS biomarker discovery and validation.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...